Novavax Inc NVAX

Novavax Inc is an American biotechnology company based in Gaithersburg, Maryland. The firm is engaged in the development of vaccines that address some of the world’s most serious and hard-to-treat infectious diseases, including COVID-19, RSV, Ebola, MERS, SARS, and seasonal influenza. The firm has a number of products at various stages in its pipeline, aimed at the prevention of a wide range of diseases. As of November 2021, the firm’s VX-CoV2373 coronavirus candidate is in advanced clinical trials. Novavax Inc was founded in 1987 and operates globally.

The company is engaged in the development of proprietary immune-stimulating adjuvants, which are being developed at Novavax AB, the firm’s wholly owned subsidiary in Sweden. The company’s primary immune-stimulating adjuvant for use in humans is Matrix-M™.

In 2020, the firm won a $1.6bn award from the US government to produce a vaccine for COVID-19 as part of the Operation Warp Speed initiative. The Coalition for Epidemic Preparedness Innovations (CEPI) has also committed to invest $388m in the development of the company’s coronavirus vaccine. The firm is listed on the NASDAQ, where it trades under the ticker NVAX.

Start monitoring the NVAX price chart for value changes by adding this stock to your eToro watchlist today.